Scientific policies and ethical economies in the development of vaccines against Zika
DOI:
https://doi.org/10.5007/2175-8034.2020v22n2p63Resumen
The Zika epidemic alarmed international health authorities, who responded by calling for efforts to develop a vaccine. The goal was to produce a biotechnology that would especially protect pregnant women and women of reproductive age, in order to prevent more babies from developing the Congenital Zika Syndrome. In this context, scientists' arguments about the need to include pregnant women in biomedical studies have been intensified as a means of ensuring that this group receives drugs with proven safety and efficacy. Here, we prioritize the perceptions of women from two states in Brazil about their hypothetical participation in a vaccine trial against Zika. Considering their hesitations concerning medical experiments and their hopes for developing a treatment for Zika, we strain the production of biotechnologies based on specific perceptions about body, risk and ethics that neglect the knowledge of the same women they are, supposedly, seeking to protect.Citas
BARRETT, Alan D. Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation. Vaccines, v. 24, 2018.
BIEHL, João. Pharmaceuticalization: AIDS treatment and global health politics. Anthropological Quarterly, v. 80, n. 4, p. 1083–1126, 2007.
BIEHL, João; PETRYNA, Adriana (Org.). When people come first: critical studies in global health. Princeton: Princeton University Press, 2013.
BLEHAR, Mary C. et. al. Enrolling pregnant women: issues in clinical research. Women’s Health Issues, v. 23, n. 1, p. e39–e45, 2013.
BRASIL, Ministério da Saúde. Boletim Epidemiológico 08. Brasília: Secretaria de Vigilância em Saúde, 2019. http://portalarquivos2.saude.gov.br/images/pdf/2019/marco/22/2019-001.pdf. Acesso em: 23 ago 2019.
BRASIL, Ministério da Saúde. Boletim Epidemiológico 46. Brasília: Secretaria de Vigilância em Saúde, 2018. http://portalarquivos2.saude.gov.br/images/pdf/2018/novembro/07/2018-053-Monitoramento-integrado-Semana-Epidemiologica-40-publicacao.pdf. Acesso em: 27 fev 2019.
BRASIL, Ministério da Saúde. Vírus Zika no Brasil: a resposta do SUS. Brasília: Ministério da Saúde, 2017. Disponível em: http://bvsms.saude.gov.br/bvs/publicacoes/virus_zika_brasil_resposta_sus.pdf. Acesso em: 23 ago 2019.
CAMPOS, Gubio; BANDEIRA, Antonio C; SARDI, Silvia I. Zika Virus Outbreak, Bahia, Brazil. Emerging Infectious Diseases, v. 21, n. 10, p. 1885–1886, 2015.
CARPENTER, Daniel. Reputation and Power: Organizational image and pharmaceutical regulation at the FDA. Princeton: Princeton University Press, 2010.
CARVALHO, Layla Pedreira. Vírus Zika e Direitos Reprodutivos: entre as políticas transnacionais, as nacionais e as ações locais. Cadernos de Gênero e Diversidade, v. 3, n. 2, p. 134–157, 2017.
COSTA, Camila. O que é falso e o que é verdadeiro nos boatos sobre zika. BBC News, 8 Fev 2016. https://www.bbc.com/portuguese/noticias/2016/02/160203_boatos_zika_cc_lab. Acesso em: 28 jan 2019.
DAS, Veena. Critical Events: An anthropological perspective on contemporary India. Delhi: Oxford University Press, 1995.
DINIZ, Debora. Zika: do sertão nordestino à ameaça global. Rio de Janeiro: Civilização Brasileira, 2016.
DINIZ, Debora. Zika in Brazil: women and children at the center of the epidemic. Brasília: LetrasLivres, 2017. Disponível em: http://anis.org.br/wp-content/uploads/2017/06/Zika-in-Brazil_Anis_2017.pdf. Acesso em: 23 ago 2019.
DINIZ, Debora; AMBROGI, Ilana. Research ethics and the Zika legacy in Brazil. Developing World Bioeth., v. 17, p. 142–143, 2017.
EDGAR, Harold; ROTHMAN, David J. New rules for new drugs: the challenge of AIDS to the regulatory process. The Milbank Quarterly, v. 68, n. 1, p. 111–142, 1990.
EPSTEIN, Steven. Bodily Differences and Collective Identities: the Politics of Gender and Race in Biomedical Research in the United States. Body & Society, v. 10, n. 2–3, p. 183–203, 1 Jun 2004.
EPSTEIN, Steven. Inclusion: The politics of difference in medical research. Chicago: The University of Chicago Press, 2007.
FADEN, Ruth; KARRON, Ruth; KRUBINER, Carleigh. An “indefensible” decision: not vaccinating pregnant and lactating women in an Ebola outbreak. STAT. 27 Ago 2018. https://www.statnews.com/2018/08/27/ebola-vaccine-pregnant-lactating-women/. Acesso em: 27 fev 2019.
FOLHA DE S.PAULO. Medo de zika faz mães brasileiras adiarem o plano de ser mães. Folha de S. Paulo, 23 Dez 2016. Disponível em: https://www1.folha.uol.com.br/equilibrioesaude/2016/12/1843896-medo-de-zika-faz-brasileiras-adiarem-plano-de-ser-mae.shtml. Acesso em: 21 fev 2019.
GOLDKIND, Sara F.; SAHIN, Leyla; GALLAURESI, Beverly. Enrolling pregnant women in research: lessons from the H1N1 Influenza Pandemic. NEJM, s. v. 362, n. 24, p. 2241–2243, 2010.
HOMBACH, Joachim et. al. Developing a vaccine against Zika. BMJ, v. 355, n. 5923, 2016.
ICH, International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. General Considerations for Clinical Trials (E8). 1997. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E8/Step4/E8_Guideline.pdf. Acesso em: 1 fev 2019.
LYERLY, Anne; LITTLE, Margaret; FADEN, Ruth. The second wave: toward responsible inclusion of pregnant women in research. IJFAB, v. 1, n. 2, p. 5-22, 2008.
MAISONNAVE, Fabiano. Oito em cada dez bebês com danos do zika nascem de mães negras. Folha de S. Paulo, São Paulo, 12 Set 2016. http://www1.folha.uol.com.br/cotidiano/2016/09/1812302-oito-em-cada-dez-bebes-com-danos-do-zica-nascem-de-maes-negras.shtml. Acesso em: 5 mar 2018.
MARQUES, Ernerto T.A; BURKE, Donald S. Tradition and innovation in development of a Zika vaccine. The Lancet, v. 391, n. 10120, p. 516-517, 2018.
MASTROIANNI, Anna C.; FADEN, Ruth; FEDERMAN, Daniel (Org.). Women and health research: ethical and legal issues of including women in clinical trials. Washington, DC: The National Academy Press, 1994.
MCCARTHY, Charles. Historical background of clinical trials involving women and minorities. Acad. Med., v. 69, n. 9, p. 695–698, 1994.
MELO, Adriana Suely de Oliveira et. al. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg? Ultrasound in Obstetrics and Gynecology, v. 47, n. 1, p. 6–7, 2016.
MINISTRY OF HEALTH. Ministério esclarece boatos sobre vírus zika. [S.l: s.n.]. 17 Dez 2015. http://portalms.saude.gov.br/noticias/agencia-saude/21291-ministerio-esclarece-boatos-sobre-virus-zika. Acesso em: 28 jan 2019.
OMER, Saad B.;BEIGI, Richard H. Pregnancy in the Time of Zika: Addressing Barriers for Developing Vaccines and Other Measures for Pregnant Women. JAMA, v. 315, n. 12, p. 1227–1228, 2016.
PAHO, Pan-American Health Organization. Zika ethics consultation: Ethics guidance on key issues raised by the outbreak. Washington, DC: PAHO, 2016. Disponível em: http://iris.paho.org/xmlui/bitstream/handle/123456789/28425/PAHOKBR16002_eng.pdf. Acesso em: 1 mar 2018.
PLOURDE, Anna; BLOCH, Evan. A literature review of Zika Virus. Emerging Infectious Diseases, v. 22, n. 7, p. 1185–1192, 2016.
SAENZ, Carla. Zika virus: ethics preparedness for old and new challenges. The Lancet, v. 4, n. 10, p. e686, 2016.
SCOTT, Parry et. al. Therapeutic paths, care and assistance in the construction of ideas about maternity and childhood in the context of the Zika virus. Interface (Botucatu), v. 22, n. 66, p. 673–684, 2018.
TAMMA, Pranita D. et. al. Safety of influenza vaccnation during pregnancy. Am J Obstet Gynecol, v. 201, n. 6, p. 547–552, 2009.
THE ETHICS WORKING GROUP ON ZIKV RESEARCH AND PREGNANCY. Ethics, pregnancy, and ZIKV vaccine research & development. Vaccine, v. 35, n. 49, p. 6819–6822, 2017.
WHO. Fifth meeting of the Emergency Committee under the International Health Regulations (2005) regarding microcephaly, other neurological disorders and Zika virus. 18 Nov 2016a. Disponível em: https://www.who.int/en/news-room/detail/18-11-2016-fifth-meeting-of-the-emergency-committee-under-the-international-health-regulations-(2005)-regarding-microcephaly-other-neurological-disorders-and-zika-virus. Acesso em: 29 jan 2019.
WHO. WHO Director-General summarizes the outcome of the Emergency Committee regarding clusters of microcephaly and Guillain-Barré syndrome. 1 Fev 2016. 2016b. Disponível em: https://www.who.int/news-room/detail/01-02-2016-who-director-general-summarizes-the-outcome-of-the-emergency-committee-regarding-clusters-of-microcephaly-and-guillain-barr%C3%A9-syndrome. Acesso em: 25 jan 2019.
WHO. “Fifth meeting of the Emergency Committee under the International Health Regulations (2005) regarding microcephaly, other neurological disorders and Zika virus”. 18 de novembro de 2016. 2016c. Disponível em: https://www.who.int/en/news-room/detail/18-11-2016-fifth-meeting-of-the-emergency-committee-under-the-international-health-regulations-(2005)-regarding-microcephaly-other-neurological-disorders-and-zika-virus.
WHO. Progress toward discovery of Zika virus vaccines and therapeutics. 23 Jul 2018. Disponível em: https://www.who.int/emergencies/diseases/zika/discovery-of-vaccines/en/. Acesso em: 25 jan 2019.
WILDER-SMITH, Annelies et al. Zika vaccines and therapeutics: landscape analysis and challenges ahead. BMC Medicine, v. 16, n. 84, 2018.
ZANLUCA, Camila et. al. First report of autochtonous transmission of Zika virus in Brazil. Mem Inst Oswaldo Cruz, v. 110, n. 4, p. 569–572, 2015.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2020 Ilha Revista de Antropologia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Os autores cedem à Ilha – Revista de Antropologia – ISSN 2175-8034 os direitos exclusivos de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Atribuição Não Comercial Compartilhar Igual (CC BY-NC-SA) 4.0 International. Esta licença permite que terceiros remixem, adaptem e criem a partir do trabalho publicado, desde que para fins não comerciais, atribuindo o devido crédito de autoria e publicação inicial neste periódico desde que adotem a mesma licença, compartilhar igual. Os autores têm autorização para assumir contratos adicionais separadamente, para distribuição não exclusiva da versão do trabalho publicada neste periódico (ex.: publicar em repositório institucional, em site pessoal, publicar uma tradução, ou como capítulo de livro), com reconhecimento de autoria e publicação inicial neste periódico, desde que para fins não comerciais e compartilhar igual.
